Skip to content
DAEWOONG THERAPEUTICS

Specialty Pipeline · 505(b)(2)

Our own medicines,from lab to launch.Already on the market.

Beyond CLOPAM and Thermicra, we develop our own improved medicines — new formulations of proven drugs, the 505(b)(2) route in US terms. Two are sold in Korea by licensing partners, and a first-in-class eyedrop leads what comes next.
Meet DWRX2008 Marketed products
Products on the market in Korea
2Products on the market in Korea
Licensees paying tech fees and royalties
8Licensees paying tech fees and royalties
SGLT2 inhibitor eyedrop, heading to the clinic
1stSGLT2 inhibitor eyedrop, heading to the clinic

01 — Flagship

DWRX2008: a first-in-class SGLT2 eyedrop

Co-developed with Daewoong Pharmaceutical and HanAll Biopharma — both have run US Phase 3 eyedrop trials.
Flagship · First-in-class

DWRX2008

The first SGLT2 inhibitor eyedrop, for diabetic retinopathy and DME

A nano-micelle drop of enavogliflozin that travels around the eye — through the conjunctiva and sclera — to reach the retina, where the pill cannot. It treats the diabetic cause, not only VEGF, without a needle in the eye.

  • Retina reached by the drop in 12 of 12 samples; 0 of 12 after the oral tablet
  • Retinal leakage cut as much as with Lucentis® and Eylea® in two disease models
  • No ocular findings in GLP safety studies; approved oral API behind it
  • Co-developed with Daewoong Pharmaceutical and HanAll Biopharma
Explore the DWRX2008 data
SGLT2 inhibitor eyedrop
1stSGLT2 inhibitor eyedrop
Leakage cut vs anti-VEGF injection
≈ IVTLeakage cut vs anti-VEGF injection
Phase 1 first patient in
Feb 2027Phase 1 first patient in

02 — Pipeline

The full development cycle, proven

Formulation, nonclinical work, clinical development, approval, technology transfer — and products earning royalties on pharmacy shelves.
  1. Formulation
  2. Nonclinical
  3. Clinical
  4. Approval
  5. Tech transfer
  6. Launch & royalty
  • DWRX2008
    Flagship

    Ophthalmology

    Diabetic retinopathy & DME

    Eyedrop · enavogliflozin (SGLT2 inhibitor)

    Stage: Phase 1. First patient in Feb 2027

  • DWRX1036

    In development

    Dermatology

    Mild-to-moderate atopic dermatitis, age 6+

    Topical

    Stage: IND-enabling. Phase 1 IND approval expected 1H 2027

  • DWRX1010

    Marketed

    Gastroenterology

    Bowel preparation before colonoscopy

    Tablet

    Stage: Marketed. Korea · 2 licensees · since Jun 2025

  • DWRX1004

    Marketed

    Gastroenterology

    Gastroesophageal reflux disease (GERD)

    Tablet · rabeprazole + antacid

    Stage: Marketed. Korea · 6 licensees · since Mar 2022

03 — Marketed products

On the market, earning royalties

We transferred the technology; licensees make and sell the products in Korea, and pay us technology fees and royalties.
Marketed · KoreaTech fee + royalty

DWRX1010

A colonoscopy prep in 20 tablets

Bowel preparation before colonoscopy

Sulfate salts with simethicone and sodium picosulfate, taken as 10 tablets the evening before and 10 on the day — fewer than the 28 of the leading tablet prep. In Phase 3 it cleansed as well as the comparator with fewer adverse drug reactions (18.1% vs 33.0%), less nausea and less headache.

2 licensees

  • Daewoong Pharmaceutical

    Cleancol® Tab. · Launched Jun 2025

  • JW Pharmaceutical

    Jcle® Tab. · Launched Jun 2025

Marketed · KoreaTech fee + royalty

DWRX1004

Faster-acting GERD relief

Gastroesophageal reflux disease

Rabeprazole combined with sodium bicarbonate: the antacid shields the PPI from stomach acid and speeds its absorption, so it starts working at least 3 hours sooner than rabeprazole alone.

6 licensees

  • Youngjin Pharm

    Rabenew® Tab. · Launched Mar 2022

  • Samjin Pharm

    Launched Mar 2022

  • Dongwha Pharm

    Launched Mar 2022

  • Dong-A ST

    Launched Mar 2022

  • Whanin Pharm

    Launched Mar 2022

  • Ildong Pharmaceutical

    Launched Mar 2022

04 — In development

Next into the clinic

Two programs are set to enter the clinic in 2027.

DWRX2008

First-in-class SGLT2 eyedrop · DR & DME

Phase 1 with first patient in planned for February 2027, then Phase 2 in DME patients.

See the data

DWRX1036

A topical for atopic dermatitis, from age six

For mild-to-moderate atopic dermatitis in patients aged six and over. IND-enabling work is under way, with Phase 1 IND approval expected in the first half of 2027.

Phase 1 IND · 1H 2027

Our specialty medicines sit alongside the Platform Pipeline. CLOPAM and Thermicra programs

License a product, or build the next one with us.

From marketed products to a first-in-class eyedrop, talk to us about rights, territories and co-development.

Talk to us

Cleancol®, Jcle® and Rabenew® are trademarks of their respective owners. Launch information from Korean trade press. Programs in development are investigational and not approved for any indication.